This is a prescription medicine. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item.
We apologise that we are unable to display a photograph of the packaging or provide you with more information regarding this prescription medicine. Australian legislation prohibits the advertisement of prescription drugs to consumers.
All of our products are APVMA or TGA approved and identical to those used by your veterinarian. Please call or email us if you have any queries about any of the products on our site.
|Drug Name and Strength||Pentosan polysulfate sodium 100 mg/mL|
|Indication||Relief of pain associated with noninfectious inflammatory joint disease in dogs and as an aid in the treatment of noninfectious inflammatory joint disease in horses: (i) osteoarthritis, especially in conditions affecting multiple joints; (ii) osteochondrosis dissecans; (iii) traumatic joint and peri-articular inflammation in working and racing dogs, and for the relief of lameness and pain in horses associated with osteoarthritis or traumatic joint disease; (iv) as treatment following intra-articular surgery, but not within the first 24 hours.|
|Contraindications||Administration to dogs with clotting defects, traumatic haemorrhage, infection, hepatic or renal failure.|
|Actions||Disease modifying osteoarthritis drug (DMOAD).Pharmacology The pharmacological activities of pentosan polysulfate considered responsible for disease modification in osteoarthritis include the following: direct anti-inflammatory activity; direct inhibition of enzymes implicated in cartilage destruction and activation of the bradykinin, complement and fibrinolytic systems (elastase, cathepsin B, hyaluronidase); indirect modulation of cartilage degradation by reduction in tissue levels of matrix metalloproteinases (MMP) concomitant with elevation of MMP inhibitor (TIMP); reduction in activity of tumour necrosis factor-α (TNF-α) at sites of inflammation; stimulation of fibrinolysis (via increased tissue plasminogen activator (tPA) and reduced tPA inhibitor) by capillary endothelium; stimulation of release of superoxide dismutase (SOD) by capillary endothelium; stimulation of hyaluronan synthesis by synovial fibroblasts; and stimulation of chondrocyte synthesis of proteoglycans and DNA.|
|Dosage and Administration||Dogs. Four 3 mg/kg (1.0 mL/33 kg) subcutaneous or intramuscular injections, with an interval of five to seven days between injections. Horses. Four 2 to 2.5 mg/kg (10 to 12.5 mL per 500 kg horse) intramuscular injections, with an interval of five to seven days between injections.|
|Storage||Store below 25°C (air conditioning.) Protect from light.|
|MSDS (external link)||Cartrophen Vet 10ml MSDS|
|Label (external link)||Cartrophen Vet 10ml Label|